Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Fibroblast growth factors, old kids on the new block.

Li X, Wang C, Xiao J, McKeehan WL, Wang F.

Semin Cell Dev Biol. 2016 May;53:155-67. doi: 10.1016/j.semcdb.2015.12.014. Epub 2016 Jan 6. Review.

PMID:
26768548
2.

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM, Farach-Carson MC.

Biomaterials. 2016 Jan;77:164-72. doi: 10.1016/j.biomaterials.2015.10.059. Epub 2015 Nov 9.

PMID:
26599623
3.

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province.

Jiang Y, Sun S, Wei W, Ren Y, Liu J, Pang D.

Oncotarget. 2015 Oct 20;6(32):34023-9. doi: 10.18632/oncotarget.5850.

4.

Interferon-γ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice.

Mitagami Y, Yasunaga J, Kinosada H, Ohshima K, Matsuoka M.

PLoS Pathog. 2015 Aug 21;11(8):e1005120. doi: 10.1371/journal.ppat.1005120. eCollection 2015 Aug. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005214.

5.

Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer: a working hypothesis.

Assinder SJ, Beniamen D, Lovicu FJ.

Biomed Res Int. 2015;2015:827462. doi: 10.1155/2015/827462. Epub 2015 May 17.

6.

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Johnston PG.

Cell Death Dis. 2014 Feb 6;5:e1046. doi: 10.1038/cddis.2014.10.

7.

Targeting fibroblast growth factor pathways in prostate cancer.

Corn PG, Wang F, McKeehan WL, Navone N.

Clin Cancer Res. 2013 Nov 1;19(21):5856-66. doi: 10.1158/1078-0432.CCR-13-1550. Epub 2013 Sep 19. Review.

8.

FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.

Peláez-García A, Barderas R, Torres S, Hernández-Varas P, Teixidó J, Bonilla F, de Herreros AG, Casal JI.

PLoS One. 2013 May 16;8(5):e63695. doi: 10.1371/journal.pone.0063695. Print 2013.

9.

FGFR1 is essential for prostate cancer progression and metastasis.

Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, Wang F, Rowley DR.

Cancer Res. 2013 Jun 15;73(12):3716-24. doi: 10.1158/0008-5472.CAN-12-3274. Epub 2013 Apr 10.

10.

Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.

Feng S, Dakhova O, Creighton CJ, Ittmann M.

Cancer Res. 2013 Apr 15;73(8):2551-62. doi: 10.1158/0008-5472.CAN-12-4108. Epub 2013 Feb 25.

11.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.

12.

Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression.

Feng S, Shao L, Yu W, Gavine P, Ittmann M.

Clin Cancer Res. 2012 Jul 15;18(14):3880-8. doi: 10.1158/1078-0432.CCR-11-3214. Epub 2012 May 9.

13.

Role and expression of FRS2 and FRS3 in prostate cancer.

Valencia T, Joseph A, Kachroo N, Darby S, Meakin S, Gnanapragasam VJ.

BMC Cancer. 2011 Nov 11;11:484. doi: 10.1186/1471-2407-11-484.

14.

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.

Armstrong K, Ahmad I, Kalna G, Tan SS, Edwards J, Robson CN, Leung HY.

Br J Cancer. 2011 Oct 25;105(9):1362-9. doi: 10.1038/bjc.2011.367. Epub 2011 Sep 27.

15.

FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.

Yu W, Feng S, Dakhova O, Creighton CJ, Cai Y, Wang J, Li R, Frolov A, Ayala G, Ittmann M.

Clin Cancer Res. 2011 Jul 1;17(13):4355-66. doi: 10.1158/1078-0432.CCR-10-2858. Epub 2011 May 27.

16.

FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.

Kobayashi M, Huang Y, Jin C, Luo Y, Okamoto T, Wang F, McKeehan WL.

Prostate. 2011 Nov;71(15):1691-700. doi: 10.1002/pros.21386. Epub 2011 Mar 28.

17.

FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.

Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, Zhang ZD, Chen M.

BMC Cancer. 2011 Feb 24;11:84. doi: 10.1186/1471-2407-11-84.

18.

The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ.

PLoS One. 2010 Dec 22;5(12):e14412. doi: 10.1371/journal.pone.0014412.

19.

Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.

Elo TD, Valve EM, Seppänen JA, Vuorikoski HJ, Mäkelä SI, Poutanen M, Kujala PM, Härkönen PL.

Neoplasia. 2010 Nov;12(11):915-27.

20.

FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex.

Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keski-Oja J, Lehti K.

Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15786-91. doi: 10.1073/pnas.0914459107. Epub 2010 Aug 23.

Items per page

Supplemental Content

Write to the Help Desk